SCHEDULE 13G: BlackRock Discloses 5.2% Stake in Candel Therapeutics
Schedule 13G Filing
BlackRock, Inc. has reported a 5.2% beneficial ownership stake in Candel Therapeutics Inc., holding 2,859,610 shares of common stock as of December 31, 2025.
Summary
- BlackRock, Inc. beneficially owns 2,859,610 shares of common stock in CANDEL THERAPEUTICS INC.
- This ownership represents 5.2% of the total outstanding common stock of CANDEL THERAPEUTICS INC.
- BlackRock, Inc. holds sole voting power over 2,821,816 shares and sole dispositive power over 2,859,610 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- BlackRock, Inc. is classified as a parent holding company (HC) for this filing.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities that may beneficially own 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: This is a factual disclosure of institutional ownership, which is neither inherently positive nor negative for the company's operational performance. It signifies a significant investor's stake.
Positives
- A significant institutional investment by BlackRock, a major global asset manager, can be viewed as a vote of confidence in Candel Therapeutics Inc.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Candel Therapeutics Inc.'s future performance or BlackRock's future investment intentions beyond the current beneficial ownership disclosure.
Management Comments
- BlackRock, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing reflects a standard disclosure of passive institutional ownership by a major asset manager in a publicly traded company. Such disclosures are common and indicate that the company's stock is part of a large investment firm's portfolio, often through various funds and mandates.
Stakeholder Impact
- Shareholders: Increased institutional ownership by a prominent firm like BlackRock may enhance market confidence and liquidity for Candel Therapeutics Inc. stock.
- Company Management: Awareness of a significant institutional holder may influence strategic decisions, though BlackRock's stated intent is passive.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Date of Power of Attorney execution by BlackRock, Inc. |
| 2025-12-31 | Date of event which requires the filing of this statement (reporting period end). |
| 2026-01-21 | Date of filing signature by BlackRock, Inc. |
Keywords
Candel Therapeutics, BlackRock, Institutional Ownership, Common Stock, Beneficial Ownership, SEC Filing, Schedule 13G, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.